References
- Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ340 b5569 (2010).
- Pao W, Girard N. Beyond EGFR and KRAS mutations in non-small cell lung cancer. Lancet Oncol. (2010) (In Press).
- Fukuoka M, Wu Y, Thongprasert S et al. Biomarker analyses from a Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J. Clin. Oncol.27(Suppl. 15), (2009) (Abstract 8006).
- Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol.11(2), 121–128 (2010).
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
- Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature448(7153), 561–566 (2007).
- Kwak EL, Camidge DR, Clark J et al. Clinical activity observed in a Phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J. Clin. Oncol.27(Suppl. 15), (2009) (Abstract 3509).
- Girard N, Mornex F. Radiotherapy for locally advanced non-small cell lung cancer. Eur. J. Cancer45(Suppl. 1), 113–125 (2009).